Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement
The protection of current influenza vaccines is limited due to the viral antigenic shifts and antigenic drifts. The universal influenza vaccine is a new hotspot in vaccine research that aims to overcome these problems. Polydopamine (PDA), a versatile biomaterial, has the advantages of an excellent b...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.693972/full |
| _version_ | 1818594975252742144 |
|---|---|
| author | Yongqing Liu Xiaoli Wang Jiangfei Zhou Shuaibing Shi Tengfei Shen Liangliang Chen Min Zhang Chengshui Liao Chen Wang |
| author_facet | Yongqing Liu Xiaoli Wang Jiangfei Zhou Shuaibing Shi Tengfei Shen Liangliang Chen Min Zhang Chengshui Liao Chen Wang |
| author_sort | Yongqing Liu |
| collection | DOAJ |
| description | The protection of current influenza vaccines is limited due to the viral antigenic shifts and antigenic drifts. The universal influenza vaccine is a new hotspot in vaccine research that aims to overcome these problems. Polydopamine (PDA), a versatile biomaterial, has the advantages of an excellent biocompatibility, controllable particle size, and distinctive drug loading approach in drug delivery systems. To enhance the immunogenicities and delivery efficiencies of H9N2 avian influenza virus (AIV) epitope peptide vaccines, PDA nanoparticles conjugated with the BPP-V and BP-IV epitope peptides were used to prepare the nano BPP-V and BP-IV epitope peptide vaccines, respectively. The characteristics of the newly developed epitope peptide vaccines were then evaluated, revealing particle sizes ranging from approximately 240 to 290 nm (PDI<0.3), indicating that the synthesized nanoparticles were stable. Simultaneously, the immunoprotective effects of nano BPP-V and BP-IV epitope peptide vaccines were assessed. The nano BPP-V and BP-IV epitope vaccines, especially nano BP-IV epitope vaccine, quickly induced anti-hemagglutinin (HA) antibody production and a sustained immune response, significantly promoted humoral and cellular immune responses, reduced viral lung damage and provided effective protection against AIV viral infection. Together, these results reveal that PDA, as a delivery carrier, can improve the immunogenicities and delivery efficiencies of H9N2 AIV nano epitope vaccines, thereby providing a theoretical basis for the design and development of PDA as a carrier of new universal influenza vaccines. |
| first_indexed | 2024-12-16T11:08:39Z |
| format | Article |
| id | doaj.art-79b4e55160534cf88cb80787f52968b9 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-16T11:08:39Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-79b4e55160534cf88cb80787f52968b92022-12-21T22:33:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-07-011210.3389/fimmu.2021.693972693972Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency ImprovementYongqing Liu0Xiaoli Wang1Jiangfei Zhou2Shuaibing Shi3Tengfei Shen4Liangliang Chen5Min Zhang6Chengshui Liao7Chen Wang8The Key Lab of Veterinary Biological Products, Henan University of Science and Technology, Luoyang, ChinaSchool of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, ChinaThe Key Lab of Veterinary Biological Products, Henan University of Science and Technology, Luoyang, ChinaThe Key Lab of Veterinary Biological Products, Henan University of Science and Technology, Luoyang, ChinaThe Key Lab of Veterinary Biological Products, Henan University of Science and Technology, Luoyang, ChinaThe Key Lab of Veterinary Biological Products, Henan University of Science and Technology, Luoyang, ChinaThe Key Lab of Veterinary Biological Products, Henan University of Science and Technology, Luoyang, ChinaThe Key Lab of Veterinary Biological Products, Henan University of Science and Technology, Luoyang, ChinaThe Key Lab of Veterinary Biological Products, Henan University of Science and Technology, Luoyang, ChinaThe protection of current influenza vaccines is limited due to the viral antigenic shifts and antigenic drifts. The universal influenza vaccine is a new hotspot in vaccine research that aims to overcome these problems. Polydopamine (PDA), a versatile biomaterial, has the advantages of an excellent biocompatibility, controllable particle size, and distinctive drug loading approach in drug delivery systems. To enhance the immunogenicities and delivery efficiencies of H9N2 avian influenza virus (AIV) epitope peptide vaccines, PDA nanoparticles conjugated with the BPP-V and BP-IV epitope peptides were used to prepare the nano BPP-V and BP-IV epitope peptide vaccines, respectively. The characteristics of the newly developed epitope peptide vaccines were then evaluated, revealing particle sizes ranging from approximately 240 to 290 nm (PDI<0.3), indicating that the synthesized nanoparticles were stable. Simultaneously, the immunoprotective effects of nano BPP-V and BP-IV epitope peptide vaccines were assessed. The nano BPP-V and BP-IV epitope vaccines, especially nano BP-IV epitope vaccine, quickly induced anti-hemagglutinin (HA) antibody production and a sustained immune response, significantly promoted humoral and cellular immune responses, reduced viral lung damage and provided effective protection against AIV viral infection. Together, these results reveal that PDA, as a delivery carrier, can improve the immunogenicities and delivery efficiencies of H9N2 AIV nano epitope vaccines, thereby providing a theoretical basis for the design and development of PDA as a carrier of new universal influenza vaccines.https://www.frontiersin.org/articles/10.3389/fimmu.2021.693972/fullpolydopaminenanoconjugatesnano BPP-V epitope vaccinenano BP-IV epitope vaccineH9N2 avian influenza virus |
| spellingShingle | Yongqing Liu Xiaoli Wang Jiangfei Zhou Shuaibing Shi Tengfei Shen Liangliang Chen Min Zhang Chengshui Liao Chen Wang Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement Frontiers in Immunology polydopamine nanoconjugates nano BPP-V epitope vaccine nano BP-IV epitope vaccine H9N2 avian influenza virus |
| title | Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement |
| title_full | Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement |
| title_fullStr | Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement |
| title_full_unstemmed | Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement |
| title_short | Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement |
| title_sort | development of pda nanoparticles for h9n2 avian influenza bpp v bp iv epitope peptide vaccines immunogenicity and delivery efficiency improvement |
| topic | polydopamine nanoconjugates nano BPP-V epitope vaccine nano BP-IV epitope vaccine H9N2 avian influenza virus |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.693972/full |
| work_keys_str_mv | AT yongqingliu developmentofpdananoparticlesforh9n2avianinfluenzabppvbpivepitopepeptidevaccinesimmunogenicityanddeliveryefficiencyimprovement AT xiaoliwang developmentofpdananoparticlesforh9n2avianinfluenzabppvbpivepitopepeptidevaccinesimmunogenicityanddeliveryefficiencyimprovement AT jiangfeizhou developmentofpdananoparticlesforh9n2avianinfluenzabppvbpivepitopepeptidevaccinesimmunogenicityanddeliveryefficiencyimprovement AT shuaibingshi developmentofpdananoparticlesforh9n2avianinfluenzabppvbpivepitopepeptidevaccinesimmunogenicityanddeliveryefficiencyimprovement AT tengfeishen developmentofpdananoparticlesforh9n2avianinfluenzabppvbpivepitopepeptidevaccinesimmunogenicityanddeliveryefficiencyimprovement AT liangliangchen developmentofpdananoparticlesforh9n2avianinfluenzabppvbpivepitopepeptidevaccinesimmunogenicityanddeliveryefficiencyimprovement AT minzhang developmentofpdananoparticlesforh9n2avianinfluenzabppvbpivepitopepeptidevaccinesimmunogenicityanddeliveryefficiencyimprovement AT chengshuiliao developmentofpdananoparticlesforh9n2avianinfluenzabppvbpivepitopepeptidevaccinesimmunogenicityanddeliveryefficiencyimprovement AT chenwang developmentofpdananoparticlesforh9n2avianinfluenzabppvbpivepitopepeptidevaccinesimmunogenicityanddeliveryefficiencyimprovement |